Provexis (PXS) AI Stock Analysis

• Market Cap: £22.87M
• Dividend Yield: N/A
• Average Volume (3M): 426.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: 61.13%
• EPS Growth: 33.33%
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 426,617
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: 0.82p ▲(15.35% Upside)

The score is held back mainly by persistent operating losses and negative cash flow despite improving revenue momentum and a debt-free balance sheet. Technicals are supportive but appear overbought, while recent corporate updates are constructive on growth initiatives; valuation remains constrained by negative earnings.

Positive Factors

Revenue Growth

Provexis's strong revenue growth indicates successful product adoption and market expansion, which can drive long-term business sustainability and competitiveness in the nutraceutical sector.

Balance Sheet Health

A robust balance sheet with no debt provides Provexis with financial stability, reducing risk and offering flexibility for future investments and strategic initiatives.

Business Model Strength

The licensing-based business model ensures recurring revenue streams and scalability, leveraging intellectual property to drive growth and maintain competitive advantage in the nutraceutical market.

Negative Factors

Profitability Challenges

Ongoing net losses highlight operational inefficiencies and challenge Provexis's ability to achieve sustainable profitability, necessitating cost management and strategic adjustments.

Cash Flow Challenges

Negative free cash flow growth suggests cash outflows exceed inflows, impacting liquidity and limiting Provexis's capacity to fund operations and invest in growth opportunities.

Net Profit Margin

A negative net profit margin indicates that Provexis is not efficiently converting revenue into profit, which could hinder its ability to reinvest in the business and sustain long-term growth.

Provexis Business Overview & Revenue Model

Company Description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

How the Company Makes Money

Provexis makes money primarily through the commercialization of its Fruitflow technology. The company generates revenue by licensing Fruitflow to manufacturers and distributors in the food and dietary supplement industries, allowing them to incorporate the ingredient into their products. Additionally, Provexis engages in collaborative partnerships and agreements with other companies to co-develop and market new products that incorporate its proprietary technology. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. The company's focus on intellectual property and innovation ensures a recurring revenue stream through licensing deals and collaborative ventures.

Provexis Financial Statement Overview

Summary

Provexis shows promising revenue growth but struggles with profitability and cash flow. The balance sheet remains robust with no debt, offering some financial stability. However, the company must address cash flow inefficiencies and manage operational costs to improve its financial health and sustainability in the long run.

Income Statement

The company has shown significant revenue growth, with a 105.68% increase from the previous year. However, profitability remains a concern with consistent net losses. The gross profit margin is 35.38%, indicating some efficiency in managing production costs, but the net profit margin is negative at -73.10%, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strong equity, with a debt-to-equity ratio of 0, indicating no financial leverage. The equity ratio stands at 145.48%, demonstrating a strong capital base relative to total assets. However, decreased stockholders' equity over the years suggests potential concerns about future capital sustainability.

Cash Flow

Cash flow analysis indicates a challenging situation with negative free cash flow growth, highlighting cash outflows exceeding inflows. The operating cash flow to net income ratio is 0.33, suggesting inefficient cash conversion from net income. The company needs to improve cash generation from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29M	1.29M	801.96K	389.92K	426.17K	505.33K
Gross Profit	532.94K	532.94K	283.80K	294.42K	380.05K	456.19K
EBITDA	-302.99K	-449.63K	-603.59K	0.00	0.00	0.00
Net Income	-452.72K	-452.72K	-586.24K	-385.24K	-224.25K	-341.01K
Balance Sheet
Total Assets	1.01M	1.01M	498.04K	845.99K	1.13M	1.29M
Cash, Cash Equivalents and Short-Term Investments	708.09K	708.09K	189.36K	379.12K	863.87K	1.08M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	248.21K	248.21K	307.45K	188.34K	157.91K	150.68K
Stockholders Equity	1.30M	1.30M	724.34K	1.19M	1.50M	1.66M
Cash Flow
Free Cash Flow	-339.79K	-338.90K	-191.50K	-519.85K	-213.79K	-262.32K
Operating Cash Flow	-339.79K	-338.90K	-191.50K	-519.85K	-213.54K	-262.07K
Investing Cash Flow	890.00	1.93K	1.73K	887.00	78.00	-250.00
Financing Cash Flow	857.63K	857.63K	0.00	35.10K	1.05M	1.05M

Provexis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Positive. The current price of 0.71 is below the 20-day moving average (MA) of 0.78, above the 50-day MA of 0.67, and above the 200-day MA of 0.65, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 72.63 is Negative, neither overbought nor oversold. The STOCH value of 86.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£73.52M	24.33	3.62%	―	1.44%	359.79%
STX	63 Neutral	£111.49M	-5.65	-396.71%	―	93.48%	51.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PXS	51 Neutral	£22.87M	-32.50	-51.21%	―	61.13%	33.33%
CHLL	42 Neutral	£4.05M	―	―	―	―	―
N4P	42 Neutral	£4.16M	-2.08	-73.08%	―	―	―

Provexis Corporate Events

Provexis Hit by Interim Sales Dip as Supply Delay Masks Expanding Fruitflow Pipeline

Provexis reported unaudited interim revenue of £364,000 for the six months to 30 September 2025, sharply lower than the prior year due to a third‑party delay in a new production run of its Fruitflow II SD ingredient, which temporarily constrained sales in August and September. Despite the short-term impact, the company has since sold out its legacy DSM-sourced inventory, booked and/or taken orders worth several hundred thousand pounds for Fruitflow II SD after the period end, and is planning at least three new production runs over the next 12 months, while continuing to deepen its commercial ties with dsm-firmenich and support BYHEALTH’s large-scale, regulatory-driven launch plans in China that could significantly expand Fruitflow’s global footprint and enhance Provexis’s long-term growth prospects.

The most recent analyst rating on (GB:PXS) stock is a Hold with a £0.82 price target. To see the full list of analyst forecasts on Provexis stock, see the GB:PXS Stock Forecast page.

Provexis Secures Shareholder Support and Advances in Chinese Market

Provexis plc announced that all resolutions were passed at its Annual General Meeting, reflecting strong shareholder support. The company continues to make strides in the Chinese market with its Fruitflow ingredient, as BYHEALTH has submitted applications for new health function claims, indicating significant investment and potential growth in the region.

Provexis Reports Strong Revenue Growth and Expands Global Reach

Provexis plc reported a 61% increase in revenue for the year ended 31 March 2025, driven by strong demand for its Fruitflow products. The company has expanded its operations with a new subsidiary in Ireland and a commercial partnership with DSM, enhancing its market reach in the EU and globally. The anticipated launch of Fruitflow-based products in China by BYHEALTH could significantly boost sales. Post-year-end developments include the completion of a new production run and plans for further production to meet rising demand, indicating a positive outlook for future growth.

Provexis Reports Strong Revenue Growth and Strategic Expansion

Provexis plc reported a 61% increase in revenue for the year ending March 2025, driven by strong demand for its Fruitflow products. The company has expanded its operations with a new subsidiary in Ireland and a long-term partnership with DSM, facilitating growth in the EU and global markets. Additionally, Provexis is collaborating with BYHEALTH to launch Fruitflow-based products in China, potentially boosting sales significantly. The company also plans multiple production runs to meet anticipated demand, indicating a positive outlook for future growth.